Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $85.00

Definium Therapeutics (NASDAQ:DFTX – Free Report) had its price target increased by JPMorgan Chase & Co. from $84.00 to $85.00 in a research report report published on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other research firms also recently weighed in on DFTX. Royal Bank Of Canada lifted their target price on Definium Therapeutics from $66.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, November 10th. Wells Fargo & Company upped their price target on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. JonesTrading raised their price target on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, October 15th. Finally, Canaccord Genuity Group set a $78.00 price objective on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Nineteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.29.

View Our Latest Analysis on Definium Therapeutics

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $29.48 on Tuesday. The stock has a market cap of $4.04 billion, a P/E ratio of -9.48 and a beta of 2.23. The stock has a 50 day simple moving average of $35.39 and a 200 day simple moving average of $30.63. The company has a current ratio of 15.53, a quick ratio of 15.53 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a 1-year low of $10.46 and a 1-year high of $49.70.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.09. Research analysts anticipate that Definium Therapeutics will post -2.94 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Matthew T. Wiley sold 3,097 shares of the company’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the completion of the sale, the insider directly owned 359,036 shares in the company, valued at approximately $13,129,946.52. This represents a 0.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $123,496.89. Following the sale, the chief financial officer directly owned 394,528 shares in the company, valued at approximately $14,427,888.96. This trade represents a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,098 shares of company stock worth $2,626,115 in the last quarter. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pinnacle Wealth Planning Services Inc. boosted its position in shares of Definium Therapeutics by 2,928.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company’s stock worth $29,000 after acquiring an additional 732 shares in the last quarter. Bessemer Group Inc. bought a new position in Definium Therapeutics in the third quarter valued at approximately $42,000. Nykredit A S acquired a new position in Definium Therapeutics during the second quarter valued at approximately $45,000. GAMMA Investing LLC raised its position in Definium Therapeutics by 28.3% during the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock valued at $59,000 after purchasing an additional 343 shares in the last quarter. Finally, Allworth Financial LP acquired a new position in Definium Therapeutics during the second quarter valued at approximately $110,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

Further Reading

Analyst Recommendations for Definium Therapeutics (NASDAQ:DFTX)

Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.